Biogen | BIIB - Operating Expenses


Biogen reported $1.96B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
ALKERMES USD 1.75B 1.43B Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026